Immunoglobulin G4 Related Disease research hub

A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease

This study is looking into a new medication, rilzabrutinib, for adults with a condition called IgG4-related disease. It compares the medication to a dummy pill to see if it's safe and helps control the disease over 52 weeks.